Compare DexCom, Inc. (DXCM) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares 7-10 Year Treasury Bond ETF — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while iShares 7-10 Year Treasury Bond ETF trades at $93.58. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | IEF | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $97.99 |
52-Week Low | $54.84 | $93.11 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
IEF, the iShares 7-10 Year Treasury Bond ETF, trades at $93.56, showing minimal daily change. The technical outlook is bearish, with moving averages signaling a downtrend and price near key support at $93. Recent news highlights a surge in bond ETF inflows as investors seek yield amid market volatility and uncertainty over Federal Reserve policy, with over $100 billion flowing into cash-like ETFs according to Benzinga on July 14, 2026.
The outlook is dominated by interest rate risk, with market sentiment cautious as debates over potential Fed hikes persist. Key opportunities include the ETF's role as a core fixed-income holding for duration exposure, while primary risks are further rate increases that would pressure bond prices and the ETF's net asset value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
